Danco Laboratories, the manufacturer of the abortion pill Mifepristone, has asked the Supreme Court to block a federal appeals court decision that would effectively end telehealth prescriptions and mail-order delivery of the medication nationwide. The emergency motion, filed Saturday, targets a ruling by the 5th U.S. Circuit Court of Appeals that reinstated a 2021 requirement for in-person dispensing of the drug.
The New York-based company warned that the lower court's order injects “immediate confusion and upheaval into highly time-sensitive medical decisions.” In its filing, Danco argued that the ruling forces patients, doctors, pharmacies, and the FDA to operate under a cloud of uncertainty about what is legally permitted.
The 5th Circuit's decision, handed down Friday, sided with Louisiana and other states challenging the FDA's approval of Mifepristone. The three-judge panel issued a temporary nationwide injunction that rolls back the agency's 2021 decision to allow the pill to be prescribed via telemedicine and shipped through the mail. The ruling threatens access for millions of women in states where abortion remains legal.
This latest legal twist comes amid a broader political battle over abortion access since the Supreme Court overturned Roe v. Wade. Democrats have vowed to fight the appeals court's decision, framing it as an attack on reproductive rights and medical autonomy. The Biden administration has signaled it may also challenge the ruling.
Legal Chaos and Patient Impact
Danco's emergency request seeks an “immediate administrative stay” while the Supreme Court decides whether to hear the case. The company argues that the 5th Circuit's ruling conflicts with FDA's scientific judgment and decades of safe use. Mifepristone, used in combination with another drug for medication abortion, has been approved by the FDA since 2000 and is considered safe and effective by major medical associations.
The case is part of a broader wave of litigation over reproductive health access. The appeals court's nationwide block on telehealth prescriptions has already prompted emergency planning by abortion providers and telehealth companies. Some clinics have scrambled to shift to in-person appointments, while others have paused services altogether.
Legal experts say the Supreme Court's decision on Danco's motion could signal how the justices view the balance between FDA regulatory authority and state-level abortion restrictions. The high court's conservative majority has shown willingness to limit abortion access in the past, but the case also raises questions about federal preemption and interstate commerce.
Political Fallout and Next Steps
The ruling has galvanized both supporters and opponents of abortion rights. Anti-abortion groups hailed the 5th Circuit's decision as a victory for safety and state sovereignty, while reproductive rights advocates condemned it as an unjustified intrusion into medical practice. Some Democratic strategists have sharply criticized the judiciary for what they see as political interference in healthcare.
Danco's motion is likely to be fast-tracked, with the Supreme Court potentially ruling within days. If the stay is granted, telehealth and mail-order access would remain in place while the appeal proceeds. If denied, the 5th Circuit's restrictions would take effect, forcing patients to obtain the pill in person from a certified provider—an obstacle for those in rural areas or states with few clinics.
The case represents a major test of the FDA's authority and the future of medication abortion, which now accounts for more than half of all abortions in the United States. The outcome could reshape how millions access reproductive care, even in states where abortion remains legal.
